Alumis INC 8-K filings

Alumis Inc. announced positive long-term data from its ONWARD3 study for envudeucitinib, showing high rates of complete skin clearance in plaque psoriasis patients and maintaining a favorable safety profile.

Alumis Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of three Class II directors and the ratification of its independent auditor.

Alumis Inc. presented an updated corporate presentation on June 29, 2026, highlighting progress and future milestones for its precision-engineered TYK2 inhibitors, envudeucitinib and A-005, targeting immune-mediated diseases.

Alumis Inc. announced its first quarter 2026 financial results, reporting a net loss of $93.1 million and highlighting positive Phase 3 data for its psoriasis drug candidate, envudeucitinib.

Envudeucitinib met all primary and secondary endpoints in two Phase 3 ONWARD trials with high Week 24 skin-clearance rates and a favorable safety profile; NDA planned for H2 2026.

Alumis Inc. announced its year-end 2025 financial results, highlighted by positive Phase 3 data for envudeucitinib in plaque psoriasis and a significant capital raise.

Alumis Inc. announced preliminary cash of $308.6 million as of December 31, 2025, and successfully completed a public offering raising approximately $345.1 million in gross proceeds.

Alumis Inc. announced positive topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials for envudeucitinib, demonstrating leading skin clearance and a favorable safety profile in moderate-to-severe plaque psoriasis.

Alumis Inc. has initiated legal action against Climb Bio, Inc. for an alleged material breach of their Asset Purchase Agreement, seeking a $3 million development milestone payment.

Alumis Inc. reported its third-quarter 2025 financial results, highlighting pipeline advancements and anticipating significant clinical data readouts for envudeucitinib in early Q1 2026 and Q3 2026.

Alumis Inc. updated its corporate presentation, showcasing a late-stage precision immunology pipeline and key near-term data readouts.

Alumis Inc. announced its second quarter 2025 financial results, highlighted by completed enrollment in key clinical trials for envudeucitinib and a strengthened financial position following its merger with ACELYRIN, Inc.

Alumis Inc. stockholders elected two Class I directors and ratified PricewaterhouseCoopers LLP as their independent registered public accounting firm for fiscal year 2025.

Alumis Inc. has finalized its merger with ACELYRIN, Inc., integrating ACELYRIN's operations and product pipeline, while ACELYRIN's latest financial disclosures reveal significant losses, a strategic pivot away from izokibep development, and ongoing litigation.

Alumis Inc. has finalized its merger with ACELYRIN, Inc., establishing a prominent clinical-stage biopharmaceutical company with a diverse portfolio and robust financial position.

Alumis Inc. stockholders voted to approve the merger with ACELYRIN, Inc. at a special meeting held on May 13, 2025.

Alumis Inc. reported its financial results for the quarter ended March 31, 2025, highlighting recent achievements and upcoming milestones, including the pending merger with ACELYRIN and progress in clinical trials.

Alumis and ACELYRIN have amended their merger agreement, increasing the ownership stake for ACELYRIN stockholders in the combined company.

Alumis grants Kaken Pharmaceutical exclusive rights to develop and commercialize ESK-001 for dermatology in Japan, securing $40 million in upfront and near-term payments.

Alumis Inc. reported its year-end 2024 financial results, highlighted recent achievements, and announced a merger agreement with ACELYRIN to create a combined company with a strong late-stage portfolio.

Alumis Inc. and ACELYRIN, INC. have released an updated presentation regarding their proposed merger, initially announced on February 6, 2025, focusing on upcoming milestones and the potential of their combined pipeline.

Alumis Inc. reports positive 52-week data from the Phase 2 STRIDE clinical trial of ESK-001, demonstrating sustained clinical responses in patients with moderate-to-severe plaque psoriasis.

Alumis and ACELYRIN have reaffirmed their commitment to merge in an all-stock transaction, with the goal of creating a leading clinical-stage biopharmaceutical company focused on immune-mediated diseases.

Alumis Inc. has approved a new Severance and Change in Control Plan to provide benefits to eligible employees upon qualifying terminations of employment.

Alumis and ACELYRIN are merging in an all-stock transaction to create a late-stage clinical biopharma company focused on immune-mediated diseases.

Alumis Inc. has revised the estimated completion dates for its Phase 2 LUMUS clinical trial for systemic lupus erythematosus (SLE), as disclosed on ClinicalTrials.gov.

Alumis Inc. announced its third quarter 2024 financial results, highlighting progress in its clinical programs for immune-mediated diseases and providing updates on key milestones.

Alumis Inc. announced its second quarter 2024 financial results, highlighted by the initiation of a Phase 3 clinical trial for ESK-001 and a Phase 1 trial for A-005, along with the completion of a $250 million IPO.

Alumis Inc. has successfully closed a private placement, issuing 2.5 million shares of common stock and raising $40 million.

Alumis Inc. has entered into a stock purchase agreement with AyurMaya Capital Management Fund, LP for a $40 million private placement of common stock.